Table 1.

The activities of drugs predicted by repositioning scores for MCF7 breast cancer cell line

Predicted Rank	Repositioned drugs	Repositioning score (mean)	Repositioning score (std)	Status*
1	raloxifene 0.0000001	0.85	0.77	FDA CT
2	paclitaxel 0.0000046	2.75	1.01	FDA CT
3	tamoxifen 0.000001	3.43	1.97	FDA CT
4	paclitaxel 0.0000001	5.46	33.73	FDA CT
5	fulvestrant 0.000001	6.31	0.98	FDA CT
6	exemestane 0.00000001	21.82	86.28	FDA CT
7	letrozole 0.000014	26.43	96.52	FDA CT
8	sulindac 0.00005	29.02	18.10	CT
9	fulvestrant 0.00000001	31.01	42.76	FDA CT
10	daunorubicin 0.000007	37.95	83.48
11	clomifene 0.0000066	38.97	20.41
12	sulindac 0.0001	46.48	19.31	CT
13	estradiol 0.00000001	53.47	79.65	FDA CT
14	imatinib 0.00001	55.64	68.28	CT
15	estradiol 0.0000001	58.60	30.09	FDA CT
16	methotrexate 0.0000088	59.80	127.82	FDA CT
17	bezafibrate 0.000011	68.08	139.31
18	doxorubicin 0.0000068	70.22	218.72	FDA CT
19	valproic acid 0.00005	76.00	69.52
20	raloxifene 0.0000078	80.74	84.14	FDA CT
21	amiloride 0.0000132	113.04	193.55
22	tamoxifen 0.000007	124.33	137.36	FDA CT

^*FDA: FDA-approved breast cancer drug, CT: Clinical trial breast cancer drug